nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

23.03.2016 | Original Article – Clinical Oncology

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

verfasst von: Gilda Schmidt, Christoph Gerlinger, Ingolf Juhasz-Böss, Elmar Stickeler, Achim Rody, Cornelia Liedtke, Pauline Wimberger, Theresa Link, Eberhard Müller, Tanja Fehm, Manuela Abel, Stefan Stein, Rainer Bohle, Jan Endrikat, Erich-Franz Solomayer

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated.

Materials and methods

We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS).

Results

1013 patients were included in this study. 447 (44.13 %) of them had a T2–4 tumour. A total of 314 (31.00 %) were nodal-positive and 714 (70.48 %) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 %) of them had a Her2-neu score 0, and 425 (41.95 %) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC.

Conclusion

The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966CrossRefPubMedPubMedCentral

Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS (2015) Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 4(9):e985930 (eCollection 2015) CrossRefPubMed

Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB et al (2010) Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15(10):1043–1049CrossRefPubMedPubMedCentral

Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G (2006) Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer 106(4):743–750CrossRefPubMed

Bahreini F, Soltanian AR, Mehdipour P (2014) A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer 22(6):615–625. doi:10.1007/s12282-014-0528-0

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728CrossRefPubMed

Bulut N, Aksoy S, Dizdar O, Dede DS, Arslan C, Dogan E et al (2011) Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Med Oncol 28(Suppl 1):S75–S79CrossRefPubMed

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334CrossRefPubMed

Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K (2013) Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8(2):e55910. doi:10.1371/journal.pone.0055910 (Epub 2013 Feb 6) CrossRefPubMedPubMedCentral

Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, Dupont WD et al (2000) Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 13(7):730–735CrossRefPubMed

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434CrossRefPubMed

D’Ippolito E, Iorio MV (2013) MicroRNAs and triple negative breast cancer. Int J Mol Sci 14(11):22202–22220CrossRefPubMedPubMedCentral

Gasparini P, Fassan M, Gascione L et al (2014) Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One. doi:10.1371/journal.pone.0088525.e88525

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657CrossRefPubMed

Hamm C, El Masri M, Poliquin G, Poliquin V, Mathews J, Kanjeekal S et al (2011) A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol 18(4):191–196CrossRefPubMedPubMedCentral

Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628–2634CrossRefPubMedPubMedCentral

Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl 1):1–11CrossRefPubMed

Kaplan HG, Malmgren JA, Atwood M (2009) T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15(5):454–460CrossRefPubMed

Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D et al (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117(16):3658–3669CrossRefPubMed

Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES (2010) Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123(1):177–187CrossRefPubMed

Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 24(Suppl 2):S36–S40. doi:10.1016/j.breast.2015.07.009 (Epub 2015 Aug 5) CrossRefPubMed

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767CrossRefPubMedPubMedCentral

Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281CrossRefPubMed

Lin C, Chien SY, Kuo SJ, Chen LS, Chen ST, Lai HW et al (2012) A 10-year follow-up of triple-negative breast cancer patients in Taiwan. Jpn J Clin Oncol 42(3):161–167CrossRefPubMed

Lipton A, Kostler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J et al (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116(22):5168–5178CrossRefPubMed

Luoh SW, Ramsey B, Hanlon NA, Troxell M, Hu Z, Chin K et al (2013) HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. Springerplus 2:386CrossRefPubMedPubMedCentral

Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E (2014) Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 7(1):278–284 (Epub 2013 Nov 14) PubMedPubMedCentral

Mrklić I, Pogorelić Z, Ćapkun V, Tomić S (2013) Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 115(4):344–348. doi:10.1016/j.acthis.2012.09.006 CrossRefPubMed

Pogoda K, Niwinska A, Murawska M, Pienkowski T (2013) Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 30(1):388CrossRefPubMedPubMedCentral

Rakha EA, El Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32CrossRefPubMed

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L et al (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13(5):R97CrossRefPubMedPubMedCentral

Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27(8):1323–1333CrossRefPubMed

Schmidt G, Meyberg-Solomayer G, Gerlinger C, Juhasz-Böss I, Herr D, Rody A, Liedtke C, Solomayer EF (2014) Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. Arch Gynecol Obstet 290(6):1221–1229. doi:10.1007/s00404-014-3331-4 (Epub 2014 Jul 11) CrossRefPubMed

Sutton LM, Cao D, Sarode V et al (2012) Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol 138(4):511–516. doi:10.1309/AJCP8AVF8FDPTZLH CrossRefPubMed

Tang D, Xu S, Zhang Q, Zhao W (2012) The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 29(2):526–533. doi:10.1007/s12032-011-9948-2 CrossRefPubMed

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMed

Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y (2013) Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 139(5):739–746. doi:10.1007/s00432-013-1376-6 (Epub 2013 Jan 26) CrossRefPubMed

Zhang L, Fang C, Xu X, Li A, Cai Q, Long X (2015) Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int 2015:357485. doi:10.1155/2015/357485 (Epub 2015 Jan 28) PubMedPubMedCentral

Titel: Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer
verfasst von: Gilda Schmidt
Christoph Gerlinger
Ingolf Juhasz-Böss
Elmar Stickeler
Achim Rody
Cornelia Liedtke
Pauline Wimberger
Theresa Link
Eberhard Müller
Tanja Fehm
Manuela Abel
Stefan Stein
Rainer Bohle
Jan Endrikat
Erich-Franz Solomayer
Publikationsdatum: 23.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2146-z

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients

Process of hepatic metastasis from pancreatic cancer: biology with clinical significance

Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival

Trends in surgery and outcomes of squamous cell vulvar cancer patients over a 16-year period (1998–2013): a population-based analysis

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie